Products for Research Use Only
RegisterLogin

Cadonilimab

CAT: 0804-HY-P99117-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99117-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC) . Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) [1][2][3][4].
CAS Number
2394841-59-7
Product Name Alternative
AK104
UNSPSC
12352203
Target
CTLA-4; PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cadonilimab.html
Purity
99.29
Solubility
H2O
Smiles
[Cadonilimab]
Molecular Weight
(198.64 kDa)
References & Citations
[1]Antonarelli G, et al. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel) . 2021 Aug 31;14 (9) :884.|[2]Kaplon H, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14 (1) :2014296.|[3]Chen PY, et al. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab. Front Immunol. 2023 Aug 3;14:1188523.|[4]Hou X, et al. Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice. Biomed Pharmacother. 2024 Jun;175:116669.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3

Alternative Products

CatalogName
T76716-01Cadonilimab
GTR18337562-01Cadonilimab Antibody
HS870216-01Research Grade Cadonilimab
E55B1268Cadonilimab (Reference antibody)
ICH5208-20mgCadonilimab Biosimilar - Research Grade
21-891Cadonilimab - Research Grade Biosimilar
GTR18697395-01Cadonilimab Human Monoclonal Antibody
591731-01PD-1xCTLA-4, Cadonilimab Biosimilar
A4002Cadonilimab (Anti-PD-1 & CTLA-4)
F2106-5Anti-PD-1 /CTLA-4 Antibody (Cadonilimab)

Popular Products